Alpha 2.0
Login Register
» Articles » PMID: 31004032

Pre-treatment CD38-positive Regulatory T Cells Affect the Durable Response to Daratumumab in Relapsed/refractory Multiple Myeloma Patients

Overview
Journal Haematologica
Specialty Hematology
Date 2019 Apr 21
PMID 31004032
Citations 21
Authors
Akihiro Kitadate
Hiroki Kobayashi
Yoshiaki Abe
Kentaro Narita
Daisuke Miura
Masami Takeuchi
Kosei Matsue
Affiliations
Soon will be listed here.
Citing Articles

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.

Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R Blood. 2024; 144(6):615-628.

PMID: 38657201 PMC: 11347796. DOI: 10.1182/blood.2023022823.

Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.

Horigome Y, Suzuki K, Suzuki T Life (Basel). 2024; 14(3).

PMID: 38541713 PMC: 10971975. DOI: 10.3390/life14030389.

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model.

van Nieuwenhuijzen N, Cuenca M, Abbink L, Jak M, Peperzak V, Minnema M EJHaem. 2024; 5(1):141-146.

PMID: 38406516 PMC: 10887349. DOI: 10.1002/jha2.824.

What happens to regulatory T cells in multiple myeloma.

Chen H, Wang X, Wang Y, Chang X Cell Death Discov. 2023; 9(1):468.

PMID: 38129374 PMC: 10739837. DOI: 10.1038/s41420-023-01765-8.

Mass cytometry analysis reveals altered immune profiles in patients with coronary artery disease.

Kott K, Chan A, Vernon S, Hansen T, Kim T, de Dreu M Clin Transl Immunology. 2023; 12(11):e1462.

PMID: 37927302 PMC: 10621005. DOI: 10.1002/cti2.1462.

References
1.
Nijhof I, Groen R, Noort W, van Kessel B, de Jong-Korlaar R, Bakker J . Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clin Cancer Res. 2014; 21(12):2802-10. DOI: 10.1158/1078-0432.CCR-14-1813. View
2.
Minnema M, van der Veer M, Aarts T, Emmelot M, Mutis T, Lokhorst H . Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia. 2008; 23(3):605-7. DOI: 10.1038/leu.2008.247. View
3.
Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L . Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res. 2017; 23(15):4290-4300. PMC: 5540790. DOI: 10.1158/1078-0432.CCR-16-3192. View
4.
Busch A, Zeh D, Janzen V, Mugge L, Wolf D, Fingerhut L . Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol. 2014; 177(2):439-53. PMC: 4226595. DOI: 10.1111/cei.12343. View
5.
Palumbo A, Chanan-Khan A, Weisel K, Nooka A, Masszi T, Beksac M . Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375(8):754-66. DOI: 10.1056/NEJMoa1606038. View